The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Advises Evantic Capital on Harvey's $550 Million Funding Round
On September 9, 2026, Harvey announced a $550 million funding round led by Diffusion and Lightspeed Venture Partners. Existing investors Sequoia, Kleiner Perkins, a16z, Coatue, Conviction, Elad Gil, Evantic Capital, GIC, Goldman Sachs Alternatives, Verified Capital, and WNDR participated in the round. New investors include Diffusion, Lightspeed, Sapphire Ventures, and Whale Rock. Wilson Sonsini Goodrich & Rosati advised Evantic Capital on the transaction.
Client Highlights
Wilson Sonsini Advises Nex on $150 Million Financing
On September 17, 2026, Nex, the company behind Nex Playground, the active play system that gets families moving together, announced more than $150 million in new equity and debt financing to support the company’s expansion. Following continued U.S. consumer growth, Nex is expanding internationally, broadening its retail distribution and growing its content ecosystem with major gaming and entertainment partners. This round of financing includes a Series E led by Baillie Gifford and BAI Capital, with participation from NBA Investments, Logitech, Medici Capital Partners, and the Raine Group, alongside a new credit facility with JPMorgan. Wilson Sonsini Goodrich & Rosati advised Nex on the transaction.
Client Highlights
Wilson Sonsini Advises Ravel on Oversubscribed $8.2 Million Seed Funding Round
On September 17, 2026, Ravel, a textile-to-textile recycling technology company, announced the closing of an oversubscribed $8.2 million Seed funding round. The investment was led by One Small Planet, with participation from AP Ventures, Overlay Capital, and Lichen Ventures, as well as follow-on investment from existing investors At One Ventures, Collateral Good, and Betterway Ventures. Wilson Sonsini Goodrich & Rosati advised Ravel on the transaction.
Client Highlights
Wilson Sonsini Advises Blaxel on its Acquisition by Baseten
On September 10, 2026, Baseten, an artificial intelligence inference company, announced that it has acquired Blaxel, an infrastructure company building secure, persistent execution environments for AI agents. The acquisition expands Baseten's platform to bring reliable, secure, and cost-effective infrastructure agents need to run code, use tools, and maintain state. Wilson Sonsini Goodrich & Rosati advised Blaxel on the transaction.
Client Highlights
Firm Advises Veteran Ventures Capital on Investment in Radian Forge's $2.5 Million Seed Financing
On September 15, 2026, Veteran Ventures Capital (VVC), an investor in dual-use national security technologies, announced that it has led the $2.5 million Series Seed preferred financing in Radian Forge, a Virginia-based advanced manufacturing company building on-demand production capacity for the U.S. maritime and defense industrial base. The financing was made through VVC's Fund II, with additional participation from the Virginia Innovation Partnership Corporation (VIPC) and Radian Forge's existing investors. Wilson Sonsini Goodrich & Rosati advised VVC on the transaction.
Client Highlights
Wilson Sonsini Advises Profound on $180 Million Series D at $1.8 Billion Valuation
On September 15, 2026, Profound, a marketing platform for the AI era, announced it raised a $180 million Series D at a $1.8 billion valuation, co-led by Sequoia Capital and Kleiner Perkins. Existing investors Lightspeed Venture Partners, Khosla Ventures, Saga Ventures, and South Park Commons also participated alongside new investor Evantic. Wilson Sonsini Goodrich & Rosati advised Profound on the transaction.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.